Retatrutide: What to Know About the Triple Agonist

Retatrutide has produced the largest weight-loss results ever reported in a Phase 3 trial of an obesity drug. In the pivotal TRIUMPH-1 study, participants on the highest dose lost an average of 70.3 lbs, or 28.3% of their body weight, over 80 weeks. Nearly half of them, 45.3%, lost at least 30% of their starting weight, a level Eli Lilly noted has historically been associated with bariatric surgery [2].

Those numbers explain why “reta” has become one of the most searched drug names on the internet. They do not mean you can get it. Retatrutide is investigational, Lilly has not yet filed it with the FDA, and anything sold online under that name is not a regulated medicine.

Here is what the evidence actually shows, what it does not show, and what would have to happen before this becomes a prescription you could fill.

What is retatrutide and how does it work?

Retatrutide is a once-weekly injectable peptide from Eli Lilly, developed under the code LY3437943. It is described as a first-in-class triple hormone receptor agonist because a single molecule activates three receptors: GIP, GLP-1 and glucagon [1].

The easiest way to understand the class is to line the three generations up:

• Semaglutide (Ozempic, Wegovy, Rybelsus) activates one receptor: GLP-1.
• Tirzepatide (Mounjaro, Zepbound) activates two: GIP and GLP-1.
• Retatrutide activates three: GIP, GLP-1 and glucagon.

GLP-1 and GIP both act on appetite and insulin. The glucagon receptor is the new piece. Glucagon signaling is associated with higher energy expenditure and with reducing fat in the liver, so adding it is meant to do something GLP-1 alone does not: burn more, not just eat less. That is the hypothesis. The trials measured outcomes, not mechanisms, so this remains the working explanation rather than a proven one.

Retatrutide is a weekly injection. Doses studied in Phase 3 ran from a 2 mg starting dose up through 4 mg, 9 mg and 12 mg, reached in stepwise increases every four weeks [1].

What did the Phase 3 trials find?

Lilly’s Phase 3 program is called TRIUMPH. It began in 2023 and enrolled more than 5,800 participants across four global registrational trials, with additional studies beyond that [1].

TRIUMPH-1: obesity without diabetes

The pivotal obesity trial, reported May 21, 2026. At 80 weeks, people on 12 mg lost an average of 70.3 lbs (28.3%) using the efficacy estimand, and 45.3% achieved at least 30% weight loss [2]. In an extension reported later, average weight loss reached 30.3% at 104 weeks among participants with a starting BMI of at least 35 who continued treatment [4].

TRIUMPH-2: obesity with type 2 diabetes

Reported July 23, 2026. This trial randomized 1,152 participants with type 2 diabetes and obesity or overweight. At 80 weeks, average weight loss was 12.7% on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg, versus 4.0% on placebo. HbA1c fell by up to 1.6 percentage points from a baseline of 7.7% [1].

People with type 2 diabetes typically lose less weight on these drugs than people without it, which makes the 20.8% figure notable.

TRIUMPH-3: severe obesity with cardiovascular disease

Also reported July 23, 2026. This trial randomized 1,949 participants with a BMI of 35 or higher and established cardiovascular disease. At 80 weeks, average weight loss was 21.6% on 9 mg and 22.6% on 12 mg, versus 3.2% on placebo [1].

Cardiovascular risk factors improved substantially on the highest dose: triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 7.5 inches, and high-sensitivity C-reactive protein down 51.2% [1].

On actual cardiovascular events, the results were less clear. Major adverse cardiovascular events happened less often than expected in both the retatrutide and placebo groups. For a five-component endpoint including all-cause death, heart attack, stroke, heart failure event or coronary revascularization, the hazard ratio was 0.82 with a 95% confidence interval of 0.55 to 1.22. For a three-component endpoint of cardiovascular death, heart attack or stroke, it was 1.12 with an interval of 0.64 to 1.96 [1]. Confidence intervals that cross 1.0 mean the study could not distinguish the result from chance. This trial was not designed as a cardiovascular outcomes trial, and a separate long-term outcomes study is underway.

TRIUMPH-4: obesity with knee osteoarthritis

The first Phase 3 to report, in December 2025. It randomized 445 adults with obesity and knee osteoarthritis. Retatrutide reduced WOMAC pain subscale scores by up to an average of 4.5 points, a 75.8% reduction, and more than one in eight treated patients were completely free from knee pain at the end of the trial. Weight loss reached up to 28.7% at 68 weeks [3][6].

What are the side effects?

The side-effect profile looks broadly like the rest of this class, with one addition that is worth knowing about.

Common adverse events. In TRIUMPH-2, comparing 4 mg, 9 mg and 12 mg with placebo: diarrhea (27.4%, 33.5%, 33.6% vs 13.2%), nausea (13.7%, 20.8%, 28.0% vs 8.0%), constipation (14.0%, 16.2%, 16.8% vs 9.4%), decreased appetite (5.8%, 12.3%, 17.1% vs 4.5%) and vomiting (5.5%, 10.2%, 15.7% vs 4.2%) [1].

Dysesthesia. This is the distinctive one. Dysesthesia is an unusual or unpleasant skin sensation, sometimes described as tingling, prickling or burning. In TRIUMPH-4 it was reported in up to 20.9% of participants on the 12 mg dose, and was described as generally mild and infrequently leading to discontinuation [5]. In TRIUMPH-2 it occurred in 4.5%, 5.6% and 7.3% across the three doses versus 0.7% on placebo, and in TRIUMPH-3 in 6.4% on both doses versus 1.3% on placebo. Lilly described these events as generally mild to moderate, with the majority resolving during treatment [1].

Discontinuation. In TRIUMPH-2, adverse-event discontinuations were 3.8% at 4 mg, 11.6% at 9 mg and 7.7% at 12 mg, versus 4.9% on placebo. In TRIUMPH-3 they were 9.8% at 9 mg and 13.5% at 12 mg, versus 4.8% on placebo [1]. In TRIUMPH-4, discontinuations related to adverse events were higher in participants with lower starting BMIs [5].

That last point matters. The bigger the weight-loss effect, the more likely it is that some people will not tolerate the highest doses. Powerful is not the same as easy.

How does retatrutide compare with what you can get today?

Honestly, and with a large caveat: none of these drugs has been compared with retatrutide head to head in the same trial. Different trial populations, different durations and different statistical methods make cross-trial comparisons unreliable. With that said, here is the rough landscape as reported by each company:

Drug	Mechanism	Reported mean weight loss	Status
Retatrutide	GIP + GLP-1 + glucagon, weekly injection	28.3% at 80 weeks	Investigational; FDA filing planned Q1 2027
Tirzepatide (Zepbound)	GIP + GLP-1, weekly injection	About 22.5% at 72 weeks	Approved
CagriSema	Amylin + GLP-1, weekly injection	22.7% at 68 weeks	Under FDA review; filed December 2025
Semaglutide 7.2 mg (Wegovy HD)	GLP-1, weekly injection	20.7% at 72 weeks	Approved March 2026
Semaglutide 2.4 mg (Wegovy)	GLP-1, weekly injection	About 17% at 68 weeks	Approved
Orforglipron (Foundayo)	GLP-1, daily pill	12.4% at 72 weeks	Approved April 2026

Sources: [1][2][8][9]

Retatrutide would sit at the top of that range if approved. It would also still be a weekly injection, and it still works partly through GLP-1, so someone who cannot tolerate GLP-1 side effects has no particular reason to expect an easier time on it.

When could retatrutide actually be available?

Lilly said in its July 23, 2026 release that it is completing the manufacturing data package required for a Biologics License Application and “plans to subsequently submit retatrutide in Q1 2027 for U.S. approval” [1].

That is the only date the company has committed to. Everything after it is uncertain:

• The FDA has to accept the filing.
• A standard review runs about 10 to 12 months, though expedited pathways exist and several obesity drugs have moved faster recently.
• Approval is never guaranteed, and the label the FDA grants may be narrower than the trials.

A realistic read is that retatrutide would not reach US pharmacies before late 2027 at the earliest, and possibly later. Anyone publishing a confident launch date right now is guessing.

Lilly has said it has the clinical data package to support submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea [1]. Trials are also running in chronic low back pain, cardiovascular and renal outcomes, and metabolic liver disease [1].

Can you buy retatrutide online?

Search for retatrutide and you will find sellers. Many describe their product as “research use only,” which is a legal workaround, not a quality statement.

Lilly’s own language is unambiguous: “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use” [1].

What that means in practice: no regulator has reviewed the manufacturing, no one has verified the identity or purity of what is in the vial, there is no FDA-approved label telling you the dose or the warnings, and there is no recourse if something goes wrong. The gray market for peptides has been a recurring subject of FDA warning letters.

If you are drawn to retatrutide because current options have not worked well enough for you, that is a real problem worth solving, and the honest place to solve it is with a healthcare provider who can look at approved options, doses you have actually tried, and whether a clinical trial you could enroll in is recruiting near you.

Is anyone else building a triple agonist?

Yes. Novo Nordisk licensed UBT251, a GLP-1/GIP/glucagon triple agonist, from China’s United Laboratories for $200 million upfront in March 2025. Chinese Phase 2 data reported in February 2026 showed up to 19.7% mean weight loss at 24 weeks, and a March 2026 diabetes readout showed HbA1c reductions of up to 2.16% [10]. Boehringer Ingelheim also began a Phase 2 trial in 2026 of a triple receptor agonist originated by the Danish company Gubra.

None of these is anywhere near retatrutide’s stage of development, but the mechanism is clearly not going to belong to one company for long.

The bottom line

Retatrutide is the most effective obesity drug yet studied in Phase 3 trials, by a meaningful margin. It is also an unapproved weekly injection with a real side-effect burden, an FDA filing that has not happened yet, and no launch date.

If you are managing obesity today, the practical decisions in front of you involve drugs that already exist. Retatrutide is worth watching, not waiting for. Bring the question to a healthcare provider, who can tell you what is available now and whether a trial might be an option.

Sources

1. Eli Lilly, “Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C” — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
2. Eli Lilly, “Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial” — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
3. Eli Lilly, “Retatrutide delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain” — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
4. American Journal of Managed Care, “Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial” — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
5. Pharmaceutical Executive, “Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial” — https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial
6. Patient Care Online, “Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4” — https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial
7. BioPharm International, “Lilly Reports Up to 28.3% Weight Loss with Retatrutide in Phase 3 Obesity Trial” — https://www.biopharminternational.com/view/lilly-reports-up-to-28-3-weight-loss-with-retatrutide-in-phase-3-obesity-trial
8. Ozmosi, “The Obesity Drug Pipeline in 2026” — https://www.ozmosi.com/obesity-drug-pipeline/
9. Novo Nordisk, “Novo Nordisk files for FDA approval of CagriSema” — https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
10. Novo Nordisk, “Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China” — https://www.biospace.com/press-releases/novo-nordisk-triple-agonist-ubt251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-china
11. HCPLive, “TRIUMPH-4: Topline Data Highlights Retatrutide’s Significant Weight Loss Effects” — https://www.hcplive.com/view/triumph-4-topline-data-highlights-retatrutide-s-significant-weight-loss-effects